Media ReleasesBionomics Limited

View All Bionomics Limited News


Bionomics Limited (ASX: BNO) Open Briefing - Outlook and Strategic Focus

Outlook and Strategic Focus after Institutional Placement
 
Open Briefing with CEO & MD Deborah Rathjen

Bionomics (ASX : BNO) is a drug discovery and development company focused on new treatments for cancer and serious disorders of the central nervous system (CNS).

Current Market Cap: $232 million

In this Open Briefing , CEO & MD Deborah Rathjen discusses
 
  - Outlook and strategic focus after  raising capital and repositioning the register
 
 - Sufficiently funded to execute licensing strategy and invest in development pipeline
 
 - Update on development and partnering  opportunities for BNC105 and BNC210



Download this document